Evaluating The Clinical Impact Of A Shortened Infusion Duration For Ramucirumab: A Population Pharmacokinetic Model-Based Approach.

Paolo Abada,Yiu-Keung Lau,Ran Wei,Lisa O’Brien,Amanda Long,Yongzhe Piao,Ling Gao

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 0|浏览4

暂无评分

摘要

191Background: Ramucirumab is a human recombinant immunoglobin G1 monoclonal antibody (mAb) antagonist of vascular endothelial growth factor receptor-2. Ramucirumab dosed at 8 mg/kg every 2 weeks o...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要